Luteinizing hormone-releasing hormone (LHRH) receptor agonists vs antagonists: a matter of the receptors?-Reference-Cited by-同舟云学术

Luteinizing hormone-releasing hormone (LHRH) receptor agonists vs antagonists: a matter of the receptors?

Published:2013-02-18 Issue:7 Volume:111 Page:1021-1030
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:BJU Int

Author:

Tolkach Yuri¹,Joniau Steven²,Van Poppel Hendrik²

Affiliation:

1. Urology Clinic; Military Medical Academy; Saint-Petersburg Russia

2. Department of Urology; University Hospital Gasthuisberg; Katholieke Universiteit Leuven; Leuven Belgium

Funder

Ferring Pharmaceuticals

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1464-410X.2013.11796.x/fullpdf

Reference73 articles.

1. Heidenreich A Bastian PJ Bellmunt J Guidelines on prostate cancer 2012 http://www.uroweb.org/gls/pdf/08%20Prostate%20Cancer_LR%20March%2013th%2012.pdf

2. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer;Klotz;BJU Int,2008

3. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer;Crawford;J Urol,2011

4. A phase 3, multicenter, open-label, randomized study of abarelixversusleuprolide acetate in men with prostate cancer;McLeod;Urology,2001

5. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer;Tomera;J Urol,2001

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integration of expression datasets to identify biomarkers for accurate Gleason scoring in Prostate Cancer;2024-08-22

2. Is Minimal Change Disease Associated with Prostate Cancer or Is Age Just a Number?;Reports;2024-08-13

3. Light-switchable diazocines as potential inhibitors of testosterone-synthesizing 17β-hydroxysteroid dehydrogenase 3;Chemico-Biological Interactions;2024-02

4. Cancer drugs with high repositioning potential for Alzheimer’s disease;Expert Opinion on Emerging Drugs;2023-10-02

5. Relugolix: Five Reasons Why the US Food and Drug Administration Should Have Exercised Restraint;European Urology;2023-02